Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Celldex Therapeutics (CLDX)

June 16, 2026 9:28 AM
UBS analyst David Dai reiterated a Buy rating and $45.00 price target on Celldex Therapeutics (NASDAQ: CLDX).The analyst commented, "CLDX ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments